Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment. However, patients eventually develop drug resi...
Gardado en:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2015-09-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Assuntos: | |
| Acceso en liña: | http://www.sciencedirect.com/science/article/pii/S2211383515001045 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|